ABSTRACT
Objectives: Cholinergic system dysfunction was found to play a key role in Alzheimer's disease (AD) pathogenesis. Therefore, the animal model of scopolamine-induced amnesia has been widely used in AD researches. Cinnamon, as a spice commonly used in cuisine, has been shown to exert some therapeutic effects. The most abundant compound in cinnamon is cinnamaldehyde which recently was shown to exert several neuroprotective effects in animal models. Therefore, this study aimed to assess whether cinnamaldehyde has the potency to prevent memory retrieval impairment and hippocampal protein kinase B (Akt) and MAPK (extracellular signal-regulated kinase (ERK)) alterations induced by scopolamine in mice.
Methods: Adult male mice were pretreated with cinnamaldehyde (12.5, 25, 40 and 100 mg/kg/oral gavage) 10 days before training. The training of passive avoidance task was performed on the 10th day and a memory retention test was done 24 h later. Scopolamine (1 mg/kg) was injected intraperitoneally, 30 min before the retention test to induce memory retrieval deficit. At the complement of the behavioral experiments, the hippocampi were isolated for western blot analysis to assess the phosphorylated and total levels of hippocampal MAPK and Akt proteins.
Results: The results showed that cinnamaldehyde pretreatment at the dose of 100 mg/kg significantly prevented the amnesic effect of scopolamine. Furthermore, cinnamaldehyde prevented scopolamine induced dysregulations of hippocampal MAPK and Akt.
Discussion: The results of the present study revealed that oral sub-chronic cinnamaldehyde administration has the capability to prevent memory retrieval deficit induced by cholinergic blockade and restores hippocampal MAPK and Akt dysregulations.
Acknowledgments
The authors wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript.
Disclosure statement
No potential conflict of interest was reported by the authors.
Additional information
Funding
Notes on contributors
Armaghan Kazerouni
Armaghan Kazerouni is a researcher with a bachelor degree in cellular and molecular biology.
Masoumeh Nazeri
Masoumeh Nazeri is a neurologist with a doctor degree in neurology. She is an assistant professor in the neurology department of Shiraz University of Medical Sciences.
Alireza Karimzadeh
Alireza Karimzadeh is a neurology resident in the neurology department of Shiraz University of Medical Sciences.
Roksana SoukhakLari
Roksana SoukhakLari is a medical student in Shiraz University of Medical Sciences.
Leila Moezi
Leila Moezi is a professor in the pharmacology department of Shiraz University of Medical Sciences.
Fatema Pirsalami
Fatema Pirsalami is a researcher with a bachelor degree in lab science. She is working in the pharmacology department of Shiraz University of Medical Sciences.
Maryam Moosavi
Maryam Moosavi is an associate professor in Nanobiology and Nanomedicine Research Center of Shiraz University of Medical Sciences.